

Patent 252/029

HE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:) Group Art Unit: 1642
Catania, A. P., et. al.	Examiner: Not Yet Assigned RECEIVED
Serial No.: 09/533,341	NOV 24 2000
Filed: 3/23/2000))
For: ANTIMICROBIAL AND ANTI- INFLAMMATORY PEPTIDES FOR USE IN HUMAN IMMUNODEFICIENCY VIRUS	TECH CENTER 1600/2908

TRANSMITTAL

Commissioner for Patents Washington, D.C. 20231

Sir:

Applicants submit the following documents with this Transmittal Letter.

- (1) Information Disclosure Statement;
- Form PTO-1449; and (2)
- Reference CB. (3)

LYON & LYON LLP

Dated: November 13, 2000

Michael J. Wise Reg. No. 34.047

Library Tower 633 West Fifth Street, Suite 4700 Los Angeles, California 90071-2066 (213) 489-1600

CERTIFICATE OF MAILING
(37 C.F.R. §1.8a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.



Patent 252/029



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:) Group Art Unit: 1642
Catania, A.P., et. al.) Examiner: Not Yet Assigned
Serial No.: 09/533,341)
Filed: 3/23/2000))
For: ANTIMICROBIAL AND ANTI- INFLAMMATORY PEPTIDES FOR USE IN HUMAN IMMUNODEFICIENCY VIRUS)))
INFORMATION DISCLOSURE STAT	TEMENT UNDER 37 CFR § 1.97(b)(3)
Commissioner for Patents Washington, D.C. 20231	
Sir:	
In compliance with the its duty under 37 CF	FR § 1.56, Applicants submit the following
reference to the Examiner for consideration:	•
Csata, M. et. al., "Enhancement of Candida epidermal cells by alpha-melanocyte stimul 121(1) 145-147 (1989).	albicans killing activity of separated human ating hormone," British Journal of Dermatology,
Applicants also submit a copy of the docum	nent and list the reference in the attached PTO
Form 1449.	
The items identified in this Information Dis	closure Statement (IDS) may or may not be
"material" pursuant to 37 CFR § 1.56 and Applicar	nts' submission thereof shall not be construed as
an admission that any such patent, publication, or o	other information referred to therein is material or
CERTIFICATE (37 C.F.R	
I hereby certify that this paper (along with any referred to as being attached date shown below with sufficient postage as First Class Mail in an envelope	addressed to the Commissioner for Patents, Washington, D.C. 20231. ROMENA R. ESTRADA
	Name of Person Mailing Paper
November 13, 2000 Date of Deposit	Signature of Person Mailing PaperLA-169620.1

considered to be material (37 CFR § 1.97(h)), or even qualifies as "prior art" under 35 USC § 102 with respect to this invention unless Applicants specifically designate as such.

The filing of this IDS shall not be construed to mean that a search has been made or that no other material information, as defined in 37 CFR § 1.56, exists.

This IDS is being filed in accordance with 37 CFR §§ 1.97 and 1.98. This IDS is believed to be timely in that it is being submitted under 37 CFR § 1.97(b)(3), that is before the mailing of the first office action. Thus, no petition or fee is required. If, however, Applicants' undersigned representative is in error in this regard, then the Examiner is requested to consider this IDS as filed under § 1.97(c) and is further authorized to charge any fee required by the filing of these papers to Lyon & Lyon's Deposit Account No. 12-2475.

Respectfully submitted,

LYON & LYON LLP

Dated: November 13, 2000

Michael J. Wise

Reg. No. 34.047

22249

PATENT TRADEMARK OFFICE

LYON & LYON LLP

Suite 4700

633 W. Fifth Street

Los Angeles, CA 90071

(213) 489-1600

Enclosures: Form PTO-1449 with reference attached

Transmittal Postcard

LA-169620.1

2